Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | BEAT-meso: Phase III trial of bevacizumab and chemo ± atezolizumab for advanced pleural mesothelioma

Melina Elpi Marmarelis, MD, University of Pennsylvania, Philadelphia, PA, discusses the BEAT-Meso trial (NCT03762018), an international Phase III study evaluating the efficacy and safety of adding atezolizumab to bevacizumab and chemotherapy in advanced pleural mesothelioma. The study showed that the addition of atezolizumab significantly increased progression-free survival (PFS) but did not significantly improve overall survival (OS). Notably, the combination of atezolizumab, bevacizumab and chemotherapy demonstrated superior outcomes in non-epithelioid cases. Grade ≥3 treatment-related adverse events were higher in the ABC arm compared to the BC arm. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.